Customer Care Associate
About the job
- 1–3 years of experience in customer experience, operations, or a related fast-paced or startup environment.
- Use strong triage judgment to determine which issues to resolve directly and which to escalate to Ops, Coaching, or Clinical.
- Produce friendly, complete, precise written responses under time pressure.
- Apply emotional intelligence by listening for the underlying patient need and calibrating communication accordingly.
- Proactively identify problems and reach out before customers ask.
- Work independently with limited oversight and take ownership of next steps.
- Maintain consistent quality and ownership while handling high ticket volume.
- Multitask effectively across multiple concurrent activities.
- Learn quickly and improve processes rather than only following existing procedures.
- Work comfortably against response time, customer satisfaction, and first-contact-resolution metrics.
- Have a genuine interest in women’s health and Evvy’s mission.
- Own a live customer support queue across email and chat while meeting a first-response target of under 24 hours.
- Communicate empathetically, effectively, and knowledgeably with customers across different personality types.
- Provide a complete and accurate answer in the first reply and achieve one-touch resolution whenever possible.
- Confirm that issues are resolved and follow through on every customer commitment.
- Track each user’s journey through testing and care end-to-end and provide proactive updates at important milestones.
- Monitor delivery, laboratory turnaround, and results exceptions using internal trackers and dashboards, and escalate patterns.
- Partner with Ops leadership to build and refine the playbook for identifying off-track cases and determining when and how to contact customers.
- Partner with Supply Chain, warehouse, logistics, offshore customer-experience agents, third-party logistics providers, and laboratory partners to resolve fulfillment issues, shipping delays, inventory discrepancies, and order exceptions.
- Surface recurring issues and root causes to Ops, Product, and Clinical teams and help turn them into process or product fixes.
- Maintain and improve standard operating procedures, macros, tags, and the knowledge base as products launch and processes change.
- Ensure support tools and processes are used consistently and update documentation when changes occur.
- Support onboarding and training as the care team grows.
- Healthcare experience is a plus.
About the company
Evvy provides an at-home, CLIA- and CLEP-certified metagenomic sequencing test to analyze the vaginal microbiome, with results reviewed by clinicians and guided by EvvyAI, an AI advisor that turns molecular findings into practical care guidance. Patients collect samples at home, send them to a lab, and receive personalized care pathways based on their microbiome profile and symptoms. The company differentiates itself by pairing clinician-reviewed, at-home mNGS testing with AI-driven recommendations, supported by peer-reviewed research and a large real-world dataset, plus collaborations on fertility and IVF studies. Its goal is to close the gender health data gap by linking microbiome biology with symptoms, treatments, and outcomes to enable precision medicine in women's health.
Company Size
51-200
Company Stage
Series B
Total Funding
$59M
Headquarters
New York City, New York
Founded
2020
Get referred to Evvy
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 15, 2026 Series B added $40 million from Catalio, US Fertility, and Labcorp.
- Evvy's fertility study with US Fertility started in 2025 and deepened in 2026.
- The UTI+ Test, launched December 2025, expands revenue beyond vaginal microbiome testing.
What critics are saying
- Fertility and cancer links remain association-heavy; 2026 payoffs depend on causal validation.
- Juno Bio's July 2026 sequencing push attacks Evvy's core diagnostic niche directly.
- If FDA or payers demand randomized outcomes data, Evvy's DTC economics break.
What makes Evvy unique
- Evvy's 2021 mNGS swab spans 700-plus microbes with CLIA and NYS CLEP review.
- The dataset reached 100,000 patients and 3,000 practitioners by September 2026.
- EvvyAI launched May 2026, turning female-specific microbiome data into clinician-reviewed guidance.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
Professional Development Budget
Paid Parental Leave
Company Social Events
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -1%2 year growth
↑ 0%September 2026 funding rounds total $1.5bn across AI, robotics and biotech. Multiple late-stage rounds raised large sums for AI models, robot chips and biotech platforms, highlighting investor focus on advanced computation and health data. Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here. Artificial intelligence. Seattle AI lab Nuance Labs raised a $50 million Series A, led by Lightspeed Venture Partners and joined by Accel, South Park Commons, NVIDIA and Define Ventures, to accelerate development of its full-duplex foundation model that perceives and generates real-time human expression for sales, customer service and education applications [3]. Hang Ten Systems, founded by former Infosys CEO Vishal Sikka, secured an additional $53 million in seed funding, bringing total capital to $85 million; the round was led by Xora (backed by Temasek) with Mayfield, Aramco Ventures, Intel CEO Lip-Bu Tan, Micron CEO Sanjay Mehrotra and Yahoo co-founder Jerry Yang also participating, to expand its AI-enabled enterprise engineering platform and global sales teams [7]. Robotics. D-Robotics closed a $400 million Series C, the largest Chinese robotics round in four years, led by Mirae Asset and Meituan with a strategic investment from a leading global internet firm and follow-on funding from existing shareholders; the capital will expand the Sunrise chip family across performance tiers and build a full software platform covering data collection, simulation and deployment, as the company reported revenue growth of several times year-on-year and cumulative chip shipments exceeding 8 million units, with its S600 chip adopted by more than 20 embodied-AI customers [1][2][4][6]. Genetic engineering. Evvy, a New York women's-health company that sequences the vaginal microbiome via an at-home swab, secured an oversubscribed $40 million Series B led by Catalio Capital Management, joined by Rethink Impact, Muse Capital, Alumni Ventures and existing backers such as LabCorp Venture Fund and General Catalyst, to fund a prospective IVF study and AI diagnostic models built on its dataset [5]. Matisse Pharmaceuticals B.V., a Dutch clinical-stage biotech developing isupartob sodium for sepsis, completed a €14 million Series A financing involving existing shareholders, Brightlands Venture Partners, LIOF and other institutional investors, with proceeds earmarked for a Phase 2 trial and related regulatory and manufacturing activities [8].
Evvy raises $40M Series B to scale ai-powered precision diagnostics & care platform for women's health. The oversubscribed round, led by Catalio Capital Management, will fund clinical validation of new AI diagnostic models as Evvy expands beyond vaginal microbiome testing into broader women's health Evvy, the pioneering precision medicine company for women's health, today announced an oversubscribed $40 million Series B led by Catalio Capital Management. Since its founding in 2021, the company has built the world's largest proprietary, clinical-grade dataset on the vaginal microbiome and women's health outcomes - and the machine learning engine, EvvyAI, that interprets large-scale biological data to transform patient care. This round will fund the validation of a new generation of AI-driven diagnostic and care models across women's health, starting with fertility. The Series B funding round includes new investors Catalio Capital Management, Rethink Impact, Muse Capital, and Alumni Ventures, alongside existing investors LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures. Founded by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy is the leading vaginal microbiome platform, serving over 100,000 patients and 3,000 practitioners with comprehensive at-home testing, personalized treatment, and longitudinal biomarker tracking. Every Evvy test is powered by CLIA-certified, NYS CLEP-approved metagenomic sequencing; ordered and interpreted by licensed clinicians; and matched with prescription treatment plans tailored to each patient's results and health history where relevant. Evvy's proprietary dataset and insights compound with every test, and their platform has already led to 13 peer-reviewed publications and abstracts, the identification of novel BV Subtypes, and the discovery of hundreds of previously uncatalogued vaginal microbiome genomes. The majority of patients come to Evvy with active vaginal symptoms or fertility challenges that standard-of-care testing has failed to explain. In the U.S., vaginal symptoms are a leading reason women seek healthcare, yet patients face 50%+ misdiagnosis rates and 60%+ recurrence rates in traditional care settings. Licensed clinicians leveraging Evvy's platform and EvvyAI are able to deliver a diagnosis to 90%+ of symptomatic patients and drive a ~50%+ reduction in bacterial vaginosis (BV) recurrence through targeted, data-driven treatment protocols. The significant improvements to patient outcomes have been validated in peer-reviewed research. Jacob Vogelstein, Co-Founder and Managing Partner at Catalio Capital Management, stated: "We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it." He continued: "Its combination of proprietary data, clinical evidence, and a growing biomarker discovery engine creates an entirely new foundation for precision women's healthcare. We believe Evvy is building the data platform that will define this category for decades to come." With the new capital, Evvy will pursue clinical validation of new EvvyAI-powered diagnostic and care models across a set of women's health conditions that collectively cost the healthcare system more than $180 billion in underserved outcomes - and expand distribution through physicians and partner channels. Evvy will also continue its collaboration with US Fertility, the nation's largest network of fertility clinics, to advance research on the role of the vaginal microbiome in fertility and reproductive health. Priyanka Jain, Co-Founder and CEO of Evvy, remarked: "Women hear 'unexplained' constantly - unexplained infertility, unexplained recurrence, unexplained pain. It's stated like a diagnosis, when it really just means medicine wasn't built to measure female biology. We set out to build the datasets and AI infrastructure that precision medicine in women's health has been missing. The vaginal microbiome is a perfect example of this - a powerful, overlooked biomarker impacting fertility, preterm birth, gynecological cancers, and more. Evvy is building the evidence, infrastructure, and partnerships needed to make precision, data-driven care the standard for women's health." About Evvy. Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy's groundbreaking Vaginal Health Test is the world's only CLIA-certified, CLEP-approved mNGS test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways, Evvy provides 100,000+ patients with data-driven, personalized care for vaginal infections, fertility, menopause, and more. Evvy is backed by 15+ peer-reviewed publications & abstracts, including validation of their novel test methodology and a study demonstrating significant improvements to patient outcomes. Evvy has built the world's largest dataset on the vaginal microbiome and is pioneering research to improve outcomes across the female lifespan.
Evvy raises $40M as it seeks to further women's health research with vaginal microbiome data. Women's health company Evvy announced Tuesday a $40 million Series B led by Catalio Capital Management. Evvy's $40 million Series B funding round, led by Catalio Capital Management, signals a significant investment in women's health research, specifically focusing on the vaginal microbiome. This area of study has been historically underfunded and understudied, despite its critical role in overall women's health. By gathering and analyzing vaginal microbiome data, Evvy aims to shed light on the complex relationships between the microbiome, women's health, and various conditions such as infertility, menstrual health, and pregnancy complications. The investment in Evvy reflects a growing recognition of the importance of women's health research and the potential for data-driven insights to drive innovation in this space. The vaginal microbiome is a rich source of data that can help researchers better understand the intricacies of women's health and develop more effective treatments. With this funding, Evvy is poised to expand its research capabilities and develop new products and services that can improve women's health outcomes. As the healthcare industry continues to shift towards personalized medicine, Evvy's work in this area could have far-reaching implications. As Evvy moves forward with its research and product development, it's worth watching how the company navigates the complex regulatory landscape surrounding women's health and microbiome research. Additionally, investors and industry observers will be keeping a close eye on Evvy's ability to translate its research findings into tangible products and services that can improve women's health outcomes. With the growing emphasis on women's health and precision medicine, Evvy's progress will be an important indicator of the potential for innovation in this space. Originally reported by techcrunch.com. ChannelNews adds analysis for technology readers. Originally reported by techcrunch.com. ChannelNews curates and briefs the technology stories that matter. Its editorial policy
Evvy raises $40M from Catalio Capital to take its vaginal microbiome data into fertility. September 15, 2026 * Evvy has raised a $40 million Series B led by Catalio Capital Management to push its vaginal microbiome platform into fertility diagnostics. * The New York company has built a dataset from more than 100,000 patients to train EvvyAI, its machine-learning engine for biomarker discovery. * The round brings Evvy's total funding to nearly $60 million, following a $14 million Series A in September 2023 led by Left Lane Capital. For years, the patients who came to Priyanka Jain with recurring infections or unexplained infertility had heard some version of the same sentence from a doctor: no clear cause found. Jain built Evvy to replace that shrug with data, starting with the vaginal microbiome. Now the startup is chasing a bigger target. Evvy has raised a $40 million Series B led by Catalio Capital Management to expand into fertility. The round is oversubscribed and includes new investors US Fertility, through its Innovation Fund, Rethink Impact, Muse Capital and Alumni Ventures, alongside returning backers General Catalyst, Left Lane Capital, Labcorp Venture Fund, BBG Ventures, Amboy Street Ventures, Ingeborg and Foreground Capital. It brings Evvy's total funding to nearly $60 million across three rounds since 2021. From vaginal health to fertility. Priyanka Jain co-founded Evvy in New York in 2021 alongside Laine Bruzek and Pita Navarro, all three women, after Jain spent four years as head of product at pymetrics, an AI hiring startup. Evvy's first product was an at-home vaginal microbiome test using metagenomic sequencing, built to catch what standard swab tests miss. It works by sequencing more than 700 bacteria and fungi from a single sample, then routing results through licensed clinicians who can prescribe treatment. That data set, now drawn from more than 100,000 patients and 3,000 practitioners, feeds EvvyAI, the company's machine-learning platform. Evvy says the work has produced 13 peer-reviewed publications, identified new bacterial vaginosis subtypes and led to a diagnosis for more than 90% of symptomatic patients, with targeted treatment cutting BV recurrence by roughly half. Competition heats up around women's health data. Evvy is entering a broader women's health market that is attracting increasingly large rounds. Juno Bio, another vaginal microbiome diagnostics company, raised $3.8 million in July 2026 to expand its sequencing platform and open a CLIA-certified women's health lab. Maven Clinic raised $125 million in 2024 at a $1.7 billion valuation, while Midi Health raised $100 million in February 2026 at a valuation above $1 billion. Evvy's pitch is that it owns the underlying diagnostic layer those broader platforms don't. Catalio, the lead investor, has a pattern of backing diagnostics plays: its portfolio includes PinkDx, a $40 million Series A for gynecological cancer diagnostics, alongside larger biotech bets like Odyssey Therapeutics and Imperative Care. "We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it," said Jacob Vogelstein, co-founder and managing partner at Catalio Capital. Jain frames the opportunity around a word she says patients hear too often: "Women hear 'unexplained' constantly - unexplained infertility, unexplained recurrence, unexplained pain. It's stated like a diagnosis, when it really just means medicine wasn't built to measure female biology." What's next? The women's health funding gap is well documented: the McKinsey Health Institute estimates that closing it could add $1 trillion to annual global GDP by 2040, largely because so little clinical data exists on conditions that affect women specifically. Whether a data company can out-execute better-funded virtual-care platforms at their own game, once it moves past its niche, is the open question this round doesn't answer.
Evvy has raised $40 million in an oversubscribed Series B round led by Catalio Capital to expand its vaginal microbiome platform into reproductive healthcare, focusing on fertility and IVF. The round included U.S. Fertility's Innovation Fund, Labcorp Venture Fund, and existing investors including General Catalyst and Left Lane Capital, bringing total funding to nearly $60 million. The company has served over 100,000 patients and partnered with 3,000 healthcare practitioners, building what it describes as the world's largest proprietary dataset on the vaginal microbiome. Ninety-six percent of patients contribute data anonymously to clinical research. Evvy's at-home Vaginal Health Test analyses over 700 bacteria and fungi using metagenomic sequencing, priced at $159 per test. The funding will scale EvvyAI, the company's data and AI platform underlying its diagnostic services. CEO Priyanka Jain aims to make vaginal microbiome screening routine preventive care, comparable to Pap smears, addressing areas where women's health research has historically been limited.